R&D at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's R&D?
- MoonLake Immunotherapeutics (MLTX) reported R&D of $54.52M in Q1 2026.
- How has MoonLake Immunotherapeutics's R&D changed year-over-year?
- MoonLake Immunotherapeutics's R&D increased by 49.5% year-over-year, from $36.46M to $54.52M.
- What is the long-term trend for MoonLake Immunotherapeutics's R&D?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's R&D has grown at a 68.7% compound annual growth rate (CAGR), from $42.25M to $202.86M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.